Table 1.

Objective responses in patients with metastatic melanoma.

Treatment (reference)TotalNumber of patients (%)
CRPROR
Dacarbazine (14) 220 0 12 (5.5%) 12 (5.5%)
Interleukin-2 (11) 270 17 (6.3%) 26 (9.6%) 43 (15.9%)
Ipilimumab (15) 540 3 (0.6%) 35 (6.4%) 38 (7.0%)
Vemurafenib (14) 219 2 (0.9%) 104 (47.5%) 106 (48.4)
Cell transfer (1) 93 20 (21.5%) 32 (34.4%) 52 (55.9%)